CN102125579B - 5位修饰的2’脱氧胞苷衍生物或其磷酸盐在制药中的新应用 - Google Patents
5位修饰的2’脱氧胞苷衍生物或其磷酸盐在制药中的新应用 Download PDFInfo
- Publication number
- CN102125579B CN102125579B CN2010106009675A CN201010600967A CN102125579B CN 102125579 B CN102125579 B CN 102125579B CN 2010106009675 A CN2010106009675 A CN 2010106009675A CN 201010600967 A CN201010600967 A CN 201010600967A CN 102125579 B CN102125579 B CN 102125579B
- Authority
- CN
- China
- Prior art keywords
- xdc
- thymidine
- dtmp
- cell
- xdcmp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 title claims abstract description 17
- 229910019142 PO4 Inorganic materials 0.000 title claims abstract description 17
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 title claims abstract description 17
- 239000010452 phosphate Substances 0.000 title claims abstract description 17
- 239000003814 drug Substances 0.000 title abstract description 49
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 11
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 claims description 68
- 238000012986 modification Methods 0.000 claims description 29
- 230000004048 modification Effects 0.000 claims description 29
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 24
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 230000000118 anti-neoplastic effect Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 201000008275 breast carcinoma Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 208000029742 colonic neoplasm Diseases 0.000 claims description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 abstract description 231
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 abstract description 114
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 abstract description 114
- 229940104230 thymidine Drugs 0.000 abstract description 114
- 210000004027 cell Anatomy 0.000 abstract description 97
- 150000004712 monophosphates Chemical class 0.000 abstract description 36
- 230000000694 effects Effects 0.000 abstract description 21
- 230000002401 inhibitory effect Effects 0.000 abstract description 17
- 230000004663 cell proliferation Effects 0.000 abstract description 11
- 230000001988 toxicity Effects 0.000 abstract description 6
- 231100000419 toxicity Toxicity 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 3
- 210000004881 tumor cell Anatomy 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 description 44
- 238000004458 analytical method Methods 0.000 description 30
- 238000002952 image-based readout Methods 0.000 description 30
- 230000005764 inhibitory process Effects 0.000 description 30
- 231100000135 cytotoxicity Toxicity 0.000 description 19
- 230000003013 cytotoxicity Effects 0.000 description 19
- 230000001640 apoptogenic effect Effects 0.000 description 17
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 16
- 229930040373 Paraformaldehyde Natural products 0.000 description 15
- 238000004043 dyeing Methods 0.000 description 15
- 229920002866 paraformaldehyde Polymers 0.000 description 15
- 210000002950 fibroblast Anatomy 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- 201000005202 lung cancer Diseases 0.000 description 13
- 208000020816 lung neoplasm Diseases 0.000 description 13
- 230000001093 anti-cancer Effects 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- HMJSYXIPNSASJY-DJLDLDEBSA-N 4-amino-5-ethynyl-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(C#C)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 HMJSYXIPNSASJY-DJLDLDEBSA-N 0.000 description 9
- 201000005296 lung carcinoma Diseases 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 125000003192 dTMP group Chemical group 0.000 description 7
- 239000003560 cancer drug Substances 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- MXHRCPNRJAMMIM-BBVRLYRLSA-N 2'-deoxyuridine Chemical class C1[C@H](O)[C@@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 MXHRCPNRJAMMIM-BBVRLYRLSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 125000001153 fluoro group Chemical group F* 0.000 description 3
- 230000012447 hatching Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 208000019065 cervical carcinoma Diseases 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- XTYLPACOIQIUEQ-RRKCRQDMSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-nitropyrimidin-2-one Chemical compound C1=C([N+]([O-])=O)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 XTYLPACOIQIUEQ-RRKCRQDMSA-N 0.000 description 1
- OEPQUYSQHIUHDR-HCWSKCQFSA-N 4-amino-1-[(2s,3r,4s,5r)-2-fluoro-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@@]1(F)[C@H](O)[C@H](O)[C@@H](CO)O1 OEPQUYSQHIUHDR-HCWSKCQFSA-N 0.000 description 1
- LNRZWAHOOLIOLA-MYINAIGISA-N 4-amino-1-[(2s,4s,5r)-2-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@]1(F)O[C@H](CO)[C@@H](O)C1 LNRZWAHOOLIOLA-MYINAIGISA-N 0.000 description 1
- DHRJKBVHFMTRGA-MYINAIGISA-N 4-amino-1-[(2s,4s,5r)-4-hydroxy-5-(hydroxymethyl)-2-iodooxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@]1(I)O[C@H](CO)[C@@H](O)C1 DHRJKBVHFMTRGA-MYINAIGISA-N 0.000 description 1
- AKVDSWDYVDOWDW-PIXDULNESA-N 4-amino-5-[(e)-2-bromoethenyl]-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(\C=C\Br)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 AKVDSWDYVDOWDW-PIXDULNESA-N 0.000 description 1
- XJDHIAUHTACXNL-VEDVMXKPSA-N C#CC(C(N)=N1)=CN(C2O[C@H](CO)C(O)=C2)C1=O Chemical compound C#CC(C(N)=N1)=CN(C2O[C@H](CO)C(O)=C2)C1=O XJDHIAUHTACXNL-VEDVMXKPSA-N 0.000 description 1
- LMFIOGUSLRNHGG-LHLIQPBNSA-L C#CC(C(N)=N1)=CN([C@@H]2O[C@H](COP([O-])([O-])=O)C(O)=C2F)C1=O Chemical compound C#CC(C(N)=N1)=CN([C@@H]2O[C@H](COP([O-])([O-])=O)C(O)=C2F)C1=O LMFIOGUSLRNHGG-LHLIQPBNSA-L 0.000 description 1
- XOOUXMJZMLABJR-MRVPVSSYSA-N CC(C(N1)=O)=CN(CC(CO[C@@H]2COP(O)(O)=O)=C2O)C1=O Chemical compound CC(C(N1)=O)=CN(CC(CO[C@@H]2COP(O)(O)=O)=C2O)C1=O XOOUXMJZMLABJR-MRVPVSSYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-SPDVFEMOSA-N CC(C(N1)=O)=CN([C@@H](C2)O[C@H](CO)C2O)C1=O Chemical compound CC(C(N1)=O)=CN([C@@H](C2)O[C@H](CO)C2O)C1=O IQFYYKKMVGJFEH-SPDVFEMOSA-N 0.000 description 1
- RBEXWVGCIBHYAD-HTQZYQBOSA-N CC(C(N1)=O)=CN([C@@H]2O[C@H](CO)C(O)=C2)C1=O Chemical compound CC(C(N1)=O)=CN([C@@H]2O[C@H](CO)C(O)=C2)C1=O RBEXWVGCIBHYAD-HTQZYQBOSA-N 0.000 description 1
- 0 CC(C(N1)=O)=CN([C@@](C2)O[C@](COP([O-])([O-])=O)C2OCC2*C2)C1=O Chemical compound CC(C(N1)=O)=CN([C@@](C2)O[C@](COP([O-])([O-])=O)C2OCC2*C2)C1=O 0.000 description 1
- 108010033174 Deoxycytidine kinase Proteins 0.000 description 1
- 102100029588 Deoxycytidine kinase Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- IDYKCXHJJGMAEV-JXBXZBNISA-N NC(C(F)=CN1[C@@H](C2)O[C@H](CO)C2O)=NC1=O Chemical compound NC(C(F)=CN1[C@@H](C2)O[C@H](CO)C2O)=NC1=O IDYKCXHJJGMAEV-JXBXZBNISA-N 0.000 description 1
- OPBLKWSMVCXQNV-JXBXZBNISA-L NC(C(F)=CN1[C@@H](C2)O[C@H](COP([O-])([O-])=O)C2O)=NC1=O Chemical compound NC(C(F)=CN1[C@@H](C2)O[C@H](COP([O-])([O-])=O)C2O)=NC1=O OPBLKWSMVCXQNV-JXBXZBNISA-L 0.000 description 1
- 108010011356 Nucleoside phosphotransferase Proteins 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 102100027624 Thymidine kinase 2, mitochondrial Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- -1 acetenyl substituent group Chemical group 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000002718 pyrimidine nucleoside Substances 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 108010036893 thymidine kinase 2 Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010106009675A CN102125579B (zh) | 2010-12-22 | 2010-12-22 | 5位修饰的2’脱氧胞苷衍生物或其磷酸盐在制药中的新应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010106009675A CN102125579B (zh) | 2010-12-22 | 2010-12-22 | 5位修饰的2’脱氧胞苷衍生物或其磷酸盐在制药中的新应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102125579A CN102125579A (zh) | 2011-07-20 |
CN102125579B true CN102125579B (zh) | 2013-12-11 |
Family
ID=44264011
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010106009675A Active CN102125579B (zh) | 2010-12-22 | 2010-12-22 | 5位修饰的2’脱氧胞苷衍生物或其磷酸盐在制药中的新应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102125579B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10420761B2 (en) * | 2013-03-15 | 2019-09-24 | University Of Florida Research Foundation, Inc. | Allosteric inhibitors of thymidylate synthase |
JP2015051946A (ja) * | 2013-09-06 | 2015-03-19 | 学校法人早稲田大学 | 細胞増殖抑制活性を有する化合物、医薬組成物及びスクリーニング方法 |
US10835524B2 (en) | 2015-06-24 | 2020-11-17 | University Of Florida Research Foundation, Incorporated | Compositions for the treatment of pancreatic cancer and uses thereof |
GB2580963B (en) * | 2019-02-01 | 2021-03-31 | Hemispherian As | Cancer therapies |
-
2010
- 2010-12-22 CN CN2010106009675A patent/CN102125579B/zh active Active
Non-Patent Citations (3)
Title |
---|
Baĭramian TL.Sister chromatid exchanges following incorporation of bromine into cytosine DNA nucleotides. I. Combined use of 5-bromdeoxycytidine and thymidine for the purpose of incorporating bromine into DNA cytosine.《Tsitologiia》.1978,第20卷(第5期),摘要. * |
John A.et al..Use of 5-fluorodeoxycytidine and Tetrahydrouridine to Exploit High Levels of deoxycytidylate deaminase in tumors to achieve DNA and Target-directed therapies.《CANCER RESEARCH》.1984,第44卷2551-2560. * |
Richard J.Localized Incorporation or Iododeoxyuridine from Polycation-complexed Iododeoxycytidylic Acid into DNA of Several Murine and Hamster Tumors.《CANCER RESEARCH》.1968,第28卷第2007-2016页. * |
Also Published As
Publication number | Publication date |
---|---|
CN102125579A (zh) | 2011-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Li et al. | Oridonin: An active diterpenoid targeting cell cycle arrest, apoptotic and autophagic pathways for cancer therapeutics | |
CN102125579B (zh) | 5位修饰的2’脱氧胞苷衍生物或其磷酸盐在制药中的新应用 | |
CN101683355A (zh) | 用于治疗癌症的包含存活蛋白寡核苷酸及吉西他滨的组合物 | |
CN106822905A (zh) | 含Survivin抑制剂和IRE1抑制剂的药物及用途 | |
CN103768080A (zh) | 一种抗耐药肿瘤的靶向制剂、制备方法及应用 | |
CN107375934A (zh) | 含有果糖‑1,6‑二磷酸的组合物在制备抗肿瘤药物中的应用 | |
JP2014530181A5 (zh) | ||
CN106913571A (zh) | 一种用于治疗肿瘤的药物及其应用 | |
CN102198150A (zh) | 双活性成分抗肿瘤药物及其应用 | |
JP6845332B2 (ja) | がん治療用医薬組成物及びその使用 | |
CN102335429B (zh) | 一种抗肿瘤药物组合物及其用途 | |
Yu et al. | Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: Does the analog matter? | |
Baronzio et al. | Early clinical and toxicological results of a combination of natural glycolysis inhibitors (METABLOC™) on cancer patients | |
CN103961353B (zh) | 黄芩素与10-羟基喜树碱的药物组合物及其应用 | |
CN102319260A (zh) | 顺铂联合伊曲康唑异构体在制备治疗肺癌药物中的应用 | |
CN104147036B (zh) | 地西他滨和奥沙利铂在制备治疗肾细胞癌组合药物中应用 | |
CN105193810B (zh) | 5‑氟尿嘧啶组合物及其在制备抗肿瘤注射剂中的应用 | |
Choi et al. | Phase I trial of neoadjuvant concurrent chemoradiotherapy with S-1 and weekly irinotecan in locally advanced rectal cancer | |
CN107921134B (zh) | 肿瘤基因甲基化调节剂的新用途及抗肿瘤药物 | |
LoRusso et al. | Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU) | |
RU2471486C2 (ru) | Противоопухолевое средство для непрерывного внутривенного введения, содержащее цитидиновое производное | |
CN112716949A (zh) | 一类抗肿瘤药物组合物、制剂和应用 | |
CN105456255A (zh) | 一种联合布雷非德菌素a的抗癌复方药物 | |
CN103479649A (zh) | 一种药物组合物及其应用 | |
CN104873514A (zh) | 一种抑制肺癌细胞增殖的药物组合物以及检测方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201013 Address after: No.7, tungda street, Science City, Huangpu District, Guangzhou City, Guangdong Province Patentee after: GUANGZHOU RIBOBIO Co.,Ltd. Address before: 510663 No. 190 Kaiyuan Avenue, Guangzhou Science City, Guangdong, Guangzhou Patentee before: GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: New application of 5-position modified 2'deoxycytidine derivative or its phosphate in pharmacy Effective date of registration: 20211223 Granted publication date: 20131211 Pledgee: Bank of China Limited Guangzhou Development Zone Branch Pledgor: GUANGZHOU RIBOBIO Co.,Ltd. Registration number: Y2021980016275 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221209 Granted publication date: 20131211 Pledgee: Bank of China Limited Guangzhou Development Zone Branch Pledgor: GUANGZHOU RIBOBIO Co.,Ltd. Registration number: Y2021980016275 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: New applications of 5-position modified 2 'Deoxycytidine derivatives or their phosphates in pharmaceuticals Effective date of registration: 20230615 Granted publication date: 20131211 Pledgee: CITIC Bank Co.,Ltd. Guangzhou Branch Pledgor: GUANGZHOU RIBOBIO Co.,Ltd. Registration number: Y2023980044095 |